Cellular immune profile in patients with non-small cell lung cancer after weekly paclitaxel therapy

被引：23

作者：

Sako, T ^{[1
]}

Burioka, N ^{[1
]}

Yasuda, K ^{[1
]}

Tomita, K ^{[1
]}

Miyata, M ^{[1
]}

Kurai, J ^{[1
]}

Chikumi, H ^{[1
]}

Watanabe, M ^{[1
]}

Suyama, H ^{[1
]}

Fukuoka, Y ^{[1
]}

Ueda, Y ^{[1
]}

Shimizu, E ^{[1
]}

机构：

[1] Tottori Univ, Fac Med, Dept Internal Med 3, Yonago, Tottori 6838504, Japan

来源：

ACTA ONCOLOGICA | 2004年 / 43卷 / 01期

关键词：

D O I：

10.1080/02841860310016226

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Paclitaxel is a new agent for advanced non-small cell lung cancer (NSCLC). Weekly doses may enhance antitumor activity while minimizing toxicity, but little is known about immune recovery. Paclitaxel (80 mg/m(2)) was administered to 10 patients with NSCLC, weekly during 3-week cycles. Natural killer (NK) activity, CD3(-)CD16(+)CD56(+) NK cells, and differential counts were monitored. NK activity appeared in all patients after treatment with paclitaxel therapy. NK activity showed a 27+/-9% decrease (mean+/-SE) on protocol day 8 and a 37+/-7% decrease on day 15 (p < 0.05) recovering to 89+/-5% of baseline on day 29. With weekly paclitaxel, a decrease in NK cell function persisted through the first cycle but then recovered. Weekly paclitaxel may be less immunosuppressive than agents such as cisplatin.

引用

页码：15 / 19

页数：5

共 28 条

[1]

Akerley W, 1997, SEMIN ONCOL, V24, P10

[2] THE USE OF NONRADIOACTIVE CHROMIUM AS AN ALTERNATIVE TO CR-51 IN NK ASSAY [J].

BORELLA, P ;

BARGELLINI, A ;

SALVIOLI, S ;

MEDICI, CI ;

COSSARIZZA, A .

JOURNAL OF IMMUNOLOGICAL METHODS, 1995, 186 (01) :101-110

[3]

Byrd-Leifer CA, 2001, EUR J IMMUNOL, V31, P2448, DOI 10.1002/1521-4141(200108)31:8&lt

[4]

2448::AID-IMMU2448&gt

[5]

3.0.CO

[6]

2-N

[7]

Choy H, 1998, CLIN CANCER RES, V4, P1931

[8] EFFECT OF NEW INVESTIGATIONAL DRUG TAXOL ON ONCOLYTIC ACTIVITY AND STIMULATION OF HUMAN-LYMPHOCYTES [J].

CHUANG, LT ;

LOTZOVA, E ;

COOK, KR ;

CRISTOFORONI, P ;

MORRIS, M ;

WHARTON, JT .

GYNECOLOGIC ONCOLOGY, 1993, 49 (03) :291-298

[9]

Garzetti GG, 1999, CANCER, V85, P2226, DOI 10.1002/(SICI)1097-0142(19990515)85:10<2226::AID-CNCR18>3.0.CO

[10]

2-X

← 1 2 3 →